Atsena Therapeutics

close-up image of an eye

Biotech

Atsena downsizes to funnel money toward new capsid program

Atsena Therapeutics has cut staff to funnel more money toward an inherited retinal disease program that just began in August.

Max Bayer Oct 5, 2023 1:47pm

ladder chutes and ladders parachute

Seagen finally finds new CEO—Chutes & Ladders

Nov 11, 2022 9:30am

Dry eye

Eyeing phase 3, Atsena raises $55M financing for gene therapy

Dec 16, 2020 7:30am